Weight-loss jabs now come as tablets too. Here is what sets the options apart.
Reviewer: Danny Chu (Envigore Prescriber)
For years, the most effective weight-loss medicines came only as weekly injections. That is changing. There are now GLP-1 weight-loss treatments you can take as a daily tablet. With two of them approved in the UK and more expected, the question we hear most is a simple one: how are they different, and which is which? Here is a plain guide to oral GLP-1 treatments, what they are, how they vary, and why one tablet is not simply swappable for another.
What is an oral GLP-1?
GLP-1 medicines work by mimicking a gut hormone that quietens appetite and slows the stomach, which is what helps you eat less without a constant battle. Until recently, they came only as injections. An oral GLP-1 does the same job in tablet form. The appeal is obvious: no needles, and a daily routine instead of a weekly injection. But how they are taken, and how they behave, varies more than you might expect.
The two now approved in the UK
Two oral GLP-1 tablets are now licensed for weight management in the UK. The Wegovy pill, oral semaglutide, was approved by the MHRA in June 2026, and is the tablet form of the medicine in the Wegovy injection.
Foundayo, orforglipron, followed in August 2026, making the UK the first country in Europe to license it, and it is a newer and quite different kind of molecule.
A third tablet, Rybelsus, is also oral semaglutide, but it is licensed for type 2 diabetes rather than weight loss, so it is a different thing again.
The big practical difference: how you take them
This is where the two split, and it matters day to day. The Wegovy pill is a peptide, which the gut breaks down easily, so it comes with strict rules. It has to be taken first thing on an empty stomach, with no more than a small sip of plain water, and nothing else by mouth for at least 30 minutes. Foundayo is a small molecule, stable in the gut, so it can be taken at any time of day, with or without food or water. If a daily fasting routine would be hard for you to keep to, that difference is a big deal.
How much weight do they help you lose?
Here is where most people want numbers, so here they are, with one caveat. These figures come from separate trials with different designs, so they are a rough guide rather than a head-to-head ranking. With that in mind, the approximate average weight loss seen over about a year is:
- Foundayo Pill: around 11 percent of body weight.
- The Wegovy Pill: around 14 percent.
- The Wegovy injection: around 15 percent.
- The Mounjaro injection: around 20 percent.
Two things stand out. The tablets are effective, comfortably into double figures. And on average the injections, Mounjaro especially, still tend to lead.
There is a reason Mounjaro sits at the top. Its medicine, tirzepatide, works on two gut hormones at once, GLP-1 and GIP, whereas the tablets, Foundayo included, work on GLP-1 alone. That extra target is part of why the injection tends to produce more weight loss. It is worth being clear that Foundayo is not an oral version of Mounjaro. It is a different, GLP-1-only medicine.
Side effects
On side effects, the tablets behave much like the injections. The main ones are digestive, nausea most commonly, and sometimes diarrhoea or constipation, usually mild and easing as the dose is built up slowly.
Foundayo and other medicines
Foundayo has one extra thing worth raising early. Because of how the body handles it, and because it slows the stomach as all these medicines do, it interacts with a number of common medications. It is not that everyone taking them is barred from Foundayo. But some combinations mean it should be avoided, and others mean a dose change, extra precautions or closer monitoring. Tell your prescriber if you take any of these:
- The contraceptive pill. Foundayo can reduce how well it works, so a non-oral or backup method is advised for a time after starting and after each dose increase.
- Certain antiviral medicines, such as those containing ritonavir, which are usually avoided with Foundayo.
- Some epilepsy, tuberculosis or similar medicines that change how your body processes drugs, such as carbamazepine, phenytoin, rifampicin or St John’s Wort.
- Diabetes medicines such as insulin or sulfonylureas, which may need reducing to avoid low blood sugar.
- Simvastatin, a common cholesterol tablet.
- Medicines with a narrow safety margin, such as thyroid tablets, warfarin, digoxin and some heart-rhythm medicines, where levels need watching.
This is not the full list, which is why the golden rule is simple. Tell your prescriber everything you take, including anything bought over the counter, so they can check it is safe for you.
Why tablets are not interchangeable
Because they are different medicines. Different molecules, different rules for taking them, different doses and different profiles. You cannot switch from one to another the way you might swap brands of paracetamol. Any change is a clinical decision, made with a prescriber who knows your history, not something to try on your own.
Who might a tablet suit?
Anyone who dislikes needles, prefers a daily routine, or simply wants a pill rather than an injection. A tablet is not automatically better, though, and for plenty of people an injection remains the stronger fit, whether for effectiveness or for the simplicity of once a week. It is an individual decision, which is exactly what a proper assessment is for.
Where we can help
If you are weighing up your options, oral weight loss tablets or injections, the right starting point is an assessment rather than a guess. Our prescribers look at your health, your history and your preferences before anything is recommended, and they will be honest about what suits you best. We will also be offering Foundayo as soon as it reaches UK pharmacies, so you can register your interest with us now. You can book a consultation at www.envigore.com.
Frequently asked questions
These questions reflect the guidance above and are reviewed by our clinical team before publication.
It is a GLP-1 weight-loss medicine taken as a daily tablet rather than a weekly injection. It works in the same way, by mimicking a gut hormone that quietens appetite. The appeal is no needles and a daily routine, though how each tablet is taken varies.
Two are licensed for weight loss: the Wegovy pill (oral semaglutide), approved in June 2026, and Foundayo (orforglipron), approved in August 2026. A third, Rybelsus, is oral semaglutide too, but licensed for type 2 diabetes rather than weight management.
Mainly how you take them. The Wegovy pill must be taken first thing on an empty stomach, with a small sip of water and nothing else for 30 minutes. Foundayo can be taken any time, with or without food or water. They are different molecules with different profiles.
In trials, the tablets produced roughly 11 to 14 percent weight loss over a year, and the injections around 15 to 20 percent. Mounjaro is highest because it works on two gut hormones rather than one. These come from separate trials, so treat them as a rough guide, not a head-to-head ranking.
Not on your own. They are different medicines with different doses and rules, so a switch is a clinical decision made with your prescriber, who will consider your history and how you have responded. It is not like swapping one brand for another.
Yes, several. It can reduce how well the contraceptive pill works, and it interacts with some antiviral, epilepsy, tuberculosis, diabetes and cholesterol medicines. It also affects drugs with a narrow safety margin, such as thyroid tablets and warfarin. It is not always a bar, but it may mean avoiding it, a dose change or monitoring, so tell your prescriber everything you take.
+ Sources
- MHRA (2026) Authorisation of oral semaglutide (Wegovy pill) in June 2026, and orforglipron (Foundayo) in August 2026, for weight management in adults. GOV.UK.
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). New England Journal of Medicine, 2025.
- Wharton, S., et al. (2025) Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). New England Journal of Medicine, 393, pp. 1796-1806.
- SURMOUNT trials of tirzepatide (Mounjaro) and STEP trials of semaglutide (Wegovy) for weight loss. New England Journal of Medicine.
- Foundayo (orforglipron) prescribing information and drug-interaction data, including oral-contraceptive, CYP3A4, simvastatin and narrow-therapeutic-index cautions.
- Manufacturer Summaries of Product Characteristics for administration, dosing and side-effect information.
About Your Clinical Team
This content was medically reviewed and approved by Danny Gian Hou Chu, a HCPC-Registered Advance Paramedic Prescriber (PA38670), who oversees all prescribing decisions at Envigore.
All prescriptions are dispensed by Right Medicine Pharmacy, a GPhC-Registered Pharmacy (No. 9012382).
Nutritional guidance and lifestyle support is provided by Veronica Giudice, a HCPC-Registered Dietitian (DT26570) and British Dietetic Association member.
Last medically reviewed: September 2026